On Tuesday, Shares of ZIOPHARM Oncology Inc.(NASDAQ:ZIOP), added 5.56% and closed at $7.60 in the last trading session. The last trading range of the stock ranges between $6.72 and $7.77. The company’s Market capitalization is $1.06 Billion with the total Outstanding Shares of 131.73 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.45 and reached to max level of $13.72. The EPS of company is strolling at -1.28. ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, recently declared the publication of data demonstrating improved persistence of genetically modified T cells targeting leukemia through utilization of its non-viral Sleeping Beauty (SB) system to co-express membrane-bound IL-15 (mbIL15) and a CD19-specific chimeric antigen receptor (CAR). The article, titled “Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells,” was published in the Proceedings of the National Academy of Sciences (PNAS) and is available online.
Using the SB system, researchers generated genetically modified T cells that preserved stem-cell memory (TSCM) by co-expressing the CAR with a fusion variant of IL-15. These engineered T cells were effective in treating established CD19+ leukemia in mice by facilitating the long-term persistence of TSCM cells sustained by signaling through mbIL15. These findings provide for a translational pipeline of immunotherapies with improved potential by combining mbIL15 and T cells with diverse specificities.
Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS), jumped 1.41% and closed at $48.16 in the last trading session. The last trading range of the stock ranges between $42.77 and $48.60. The company’s Market capitalization is $6.51 Billion with the total Outstanding Shares of 121.20 million. During the 52-week trading session the minimum price at which share price traded, registered at $19.59 and reached to max level of $63.71. The EPS of company is strolling at -1.53. Akcea Therapeutics, a wholly-owned partner of Ionis Pharmaceuticals, Inc. (NASDAQ:IONIS), recently declared positive results from an interim analysis of a Phase 1/2a study of IONIS-ANGPTL3-LRx. In this study, subjects with elevated triglycerides achieved substantial and statistically noteworthymean reductions in angiopoietin-like 3 (ANGPTL3), triglycerides and LDL-cholesterol of up to 83 percent, 66 percent, and 35 percent, respectively. The study was presented recently at the American Heart Association Scientific Sessions by Sotirios Tsimikas, M.D., professor of medicine and director of vascular medicine at the University of California, San Diego, and vice president of clinical development at Ionis Pharmaceuticals.